Hepatitis Monthly
IL-33 is a novel member of the IL-1 family, which has been shown to play an important role in T helper 2 (Th2)-associated immune responses. Recent studies have suggested a possible role for IL-33 in the pathogenesis of liver damage during acute and chronic hepatitis; furthermore, IL-33 may be involved in the development and progression of liver fibrosis.
To evaluate serum IL-33 levels in a group of patients with chronic hepatitis C (CHC) genotype 1b at enrolment and after a course of pegylated (PEG)-IFN plus ribavirin.
60 patients with chronic hepatitis C (CHC) and 65 healthy controls were examined and compared for serum IL-33 levels by ELISA. All CHC patients were submitted to liver biopsy either before starting antiviral treatment or during post-treatment follow up. We evaluated whether post-treatment IL-33 concentration was associated with histologic outcome as well as with virologic response to therapy.
Serum IL-33 levels were significantly higher among CHC patients in comparison with healthy controls. IL-33 concentration was lower among patients with a METAVIR fibrosis score F1-F2, compared with those having a more advanced liver disease (METAVIR stage F3-F4). In addition, sustained virologic response (SVR) was associated with a significant drop in IL-33 levels, whereas no changes were found among relapsers and nonresponders. Analogously, patients experiencing liver histologic improvement after antiviral therapy had lower post-treatment IL-33 levels in comparison with baseline values. Contrarily, no variations were detected among subjects with worsened or stable histologic features.
IL-33 may represent a new and easy-to-detect biomarker for the diagnosis of liver damage in CHC patients, as it appears to be modulated in parallel with biochemical and histologic parameters, such as ALT levels and liver fibrosis. Furthermore, considering that serum IL-33 concentration was significantly reduced following a successful course of antiviral treatment, this cytokine may also represent a sensitive indicator of SVR.
© 2012, Author(s). This open-access article is available under the Creative Commons Attribution 4.0 (CC BY 4.0) International License (https://creativecommons.org/licenses/by/4.0/), which allows for unrestricted use, distribution, and reproduction in any medium, provided that the original work is properly cited.
Ashrafi Hafez A, Ahmadi Vasmehjani A, Baharlou R, Mousavi Nasab SD, Davami MH, et al. Analytical Assessment of Interleukin - 23 and -27 Cytokines in Healthy People and Patients With Hepatitis C Virus Infection (Genotypes 1 and 3a). Hepat Mon. 2014;14(9):e21000. doi: https://doi.org/10.5812/hepatmon.21000
Najafizadeh M, Farhadi N, Sarkari B. Th1 Cytokine Profiles in Hepatitis C Virus Infected Patients and Their Contribution to Inflammatory Responses. Shiraz E-Med J. 2007;8(1):. doi:
Metanat M, Alijani E, Ansari-Moghaddam A, Bahrehmand F, Khalili M, et al. The Relationship Between Serum IL-17 Level and Viral Load in Chronic Hepatitis B. Arch Clin Infect Dis. 2019;14(3):e68172. doi: https://doi.org/10.5812/archcid.68172
Rokhtabnak N, Ataollahi MR, Asadipour M, Ali-Hassanzadeh M, Fazeli P, et al. Negative Correlation of Interleukin-38 Serum Level with Alkaline Phosphatase and Persistent Hepatitis C Infection. Shiraz E-Med J. 2022;23(9):e121969. doi: https://doi.org/10.5812/semj-121969
Hosseini Khorami SH, Nejatollahi F, Davarpanah MA. Serum Levels of Interleukin-4, Interleukin-10 and Interferon-γ in Patients with Chronic Hepatitis B Infection. Hepat Mon. 2018;18(4):e60377. doi: https://doi.org/10.5812/hepatmon.60377
Checking
Last Update: 1 week ago
Last Update: 1 week ago
Last Update: 1 week ago
Last Update: 5 days ago
Ordering Reprints
Articles are published under the Creative Commons license stated on each article. No permission or royalty fee is required for uses permitted by that license. CCC handles optional bulk and customized reprint orders. Any quotation covers production and delivery services only, not copyright permission. > Request Reprints from CCC
Author(s):
